BNP Paribas Financial Markets
ACHL

BNP Paribas Financial Markets’s Achilles Therapeutics ACHL Stock Holding History

BNP Paribas Financial Markets’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-50,189
Closed -$57.2K – 5628
2024
Q4 		$57.2K Buy
+50,189
New +$51.7K ﹤0.01% 4381

Other funds holding ACHL

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BAM
Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

BNP Paribas Financial Markets's ACHL Position: Q1 2025 in Review

BNP Paribas Financial Markets sold out of Achilles Therapeutics (ACHL) in Q1 2025, closing a stake of 50,189 shares — an estimated $57.2K sold.

BNP Paribas Financial Markets first reported a position in ACHL in Q4 2024 and held it in 1 quarter. The position peaked at $57.2K in Q4 2024. 6 funds tracked by Wall St. Rank hold ACHL as of Q1 2025.

  • BNP Paribas Financial Markets reported no remaining Achilles Therapeutics position as of Q1 2025 after selling out during the quarter.
  • BNP Paribas Financial Markets sold 50,189 Achilles Therapeutics shares in Q1 2025, an estimated $57.2K.
  • BNP Paribas Financial Markets first reported a position in Achilles Therapeutics in Q4 2024 and held it in 1 quarter.
  • BNP Paribas Financial Markets's Achilles Therapeutics position peaked at $57.2K in Q4 2024.
  • 6 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2025.

Based on BNP Paribas Financial Markets's 13F filing for Q1 2025, filed 14 May 2025.